May 4th, 2015
Increased Mortality Risk Found With Digoxin
Larry Husten, PHD
For more than 200 years physicians have been trying to figure out how and when to use digoxin. Although it has a narrow therapeutic window and potentially dangerous interactions with other drugs, it is endorsed by current guidelines and widely given to patients with heart failure (HF) and atrial fibrillation (AF). However, there have been no […]
April 9th, 2015
Digoxin Use in Afib: Revisiting Data from ROCKET AF
Manesh R. Patel, MD
Manesh R. Patel discusses his research group’s retrospective analysis of data on digoxin use among patients with atrial fibrillation in the ROCKET AF trial.
August 11th, 2014
What’s the Next Phase for Digoxin in Patients with Atrial Fibrillation?
Mintu Turakhia, MD MAS
Mintu P. Turakhia discusses his observational study of digoxin use and mortality risk in patients with atrial fibrillation, using data from the TREAT-AF study.
August 11th, 2014
Study Offers Little Support for an Old Drug
Larry Husten, PHD
Digoxin is one of the oldest drugs in the cardiovascular arsenal, derived from the foxglove plant and first described in the 18th century by William Withering. It is frequently used in patients with heart failure (HF) and with atrial fibrillation (AF). The few trials supporting its use were performed in HF patients before newer treatments […]
October 17th, 2013
Questioning Digoxin Use for Patients with Systolic HF
James Freeman, MD, MPH, MS
James Freeman discusses his research group’s evaluation of the contemporary effectiveness and safety of digoxin therapy among adults with newly diagnosed systolic heart failure.
September 24th, 2013
Study Raises Questions About Digoxin Use Today
Larry Husten, PHD
Digoxin is one of the oldest medicines in the cardiovascular arsenal. When William Withering identified it as the active ingredient in the foxglove plant more than 200 years ago, he was only codifying a longstanding folk remedy for heart failure, or “dropsy” as it was known then. Digoxin fully entered the modern era with the publication […]
March 21st, 2013
DIGging In: Three Reasons Why the Recent Digoxin Study Is Not Relevant to Readmission
Harlan M. Krumholz, MD, SM
The evidence is just not compelling that this this drug would reduce hospital readmissions
NEJM Journal Watch — Recent Cardiology Articles- Sex-Based Disparity in CABG Outcomes: Are We Moving Toward Parity?
- Can Genetic and Social Risk Scores Improve Cardiac Risk Prediction?
- Extensive Ablation vs. Pulmonary Vein Isolation in Persistent Atrial Fibrillation
- Can a Novel Stent Design Improve Long-Term Outcomes of Percutaneous Coronary Intervention?
- Are Angiographically-Derived Coronary Physiology Measurements Ready for Use in the Cath Lab?